Skip to main content
Rachel Buchsbaum, MD, Oncology, Boston, MA, Tufts Medical Center

RachelBuchsbaumMD

Oncology Boston, MA

Breast Cancer, Hematologic Oncology

Chief, Division of Hematology Oncology, Tufts Medical Center

Dr. Buchsbaum is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Buchsbaum's full profile

Already have an account?

Education & Training

  • Tufts Medical Center
    Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1988 - 1992
  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1985 - 1988
  • Weill Cornell Medicine
    Weill Cornell MedicineClass of 1985
  • Harvard University
    Harvard UniversityA.B., Chemistry & Physics, Cum Laude, 1980

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1987 - 2025
  • ME State Medical License
    ME State Medical License 2020 - 2021
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Exceptional Women in Medicine Castle Connolly, 2017
  • Boston's Top Doctors Boston Magazine, 2017
  • Zucker Clinical Teaching Prize for Innovation in Medical Education Tufts University School of Medicine, 2015

Publications & Presentations

PubMed

Abstracts/Posters

  • Supervised Machine Learning Algorithms Using Patient Related Factors to Predict in-Hospital Mortality Following Acute Myeloid Leukemia Therapy
    Rachel J. Buchsbaum, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

  • Fulfilling Common Program Requirements VI.C: Well-Being 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019

Press Mentions

  • Debunking Myths About Cancer
    Debunking Myths About CancerJune 10th, 2022
  • Efficacy of Margetuximab vs Trastuzumab in Patients with Pretreated ERBB2-Positive Advanced Breast Cancer
    Efficacy of Margetuximab vs Trastuzumab in Patients with Pretreated ERBB2-Positive Advanced Breast CancerJanuary 22nd, 2021

Hospital Affiliations